% | $
Quotes you view appear here for quick access.

Alexza Pharmaceuticals Inc. Message Board

  • medicalstara medicalstara Jul 16, 2013 7:58 AM Flag

    TBUFF (Mcap $19 M) Price:$0.39 // 7 Drugs launched & 1 NDA filing for Potential Blockbuster in 2014

    This REAL Unknow and Low Float Gem has already 7 Products on the Market ,1 is awaiting Approval in Canada and another 1 is close to US-NDA filing for Potential Blockbuster . The Market Cap of $19 M is really a BIG JOKE for a Company which hits $13 Million in revenue last year and growing fast . Load up the truck before the Investors discover this brutally underpriced Stock .

    TGT $3-5 within 12 Months ..GLTA

    Tribute Pharma (TBUFF)

    Market Cap : $19 M
    Cash: $3 M

    Shares Out : 51 M ( 29 M shares are held by Management alone )


    Product Indication Geographic Right Market Size

    Bezalip® SR Mixed dyslipidemia US & Canada $20 B

    NeoVisc® Osteoarthritis of the knee Global $1.4 B

    Soriatane® Moderate to severe psoriasis Canada $210 M

    Uracyst® Interstitial cystitis Global $151 M

    CAMBIA® Acute migraine headaches Canada $150 M

    Collatamp G® Prevention of post-operative infection Canada $20 M

    Gelfoam® Hemostatic device Canada $30 M

    MycoVa™ Nail fungus Canada $30 M

    Canadian Business Includes 7 Marketed Products Including Recently Launched CAMBIA .Tribute sells products in both the primary care and specialty care markets.CAMBIA was launched in October 2012 to compete in the $150 million Canadian migraine market and is expected to be a key contributor to revenue growth in 2013.CAMBIA is a novel, patent-protected, fast-acting, new treatment option for people suffering from acute migraine attacks.Tribute has also entered into a promotional agreement with Pfizer Canada for the exclusive Canadian promotional rights to Gelfoam® in Canada. MycoVa is currently pending regulatory approval in Canada.


    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.9531-0.0075(-0.78%)May 27 4:00 PMEDT